Rigel Pharmaceuticals Inc. (RIGL)
RIGL trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1034842/000103484226000015/0001034842-26-000015-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | RIGL on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2000 |
| SEC CIK | 0001034842 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $294.3M |
| Net income | $367.0M |
| Operating income | $125.5M |
| Net margin | 124.7% |
| Operating margin | 42.6% |
| Revenue growth | +64.1% |
| Cash | $40.6M |
| Total assets | $513.6M |
| P/E (computed) | 2.2× |
| P/S (computed) | 2.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $46.6M cash; operating cash flow $22.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 18,829,972 (2026-11-02); 18,151,344 a year earlier; 174,369,503 three years earlier. 3y figure adjusted for splits (1-for-10 overall). | Cover page 2026-11-02 |
| Reverse splits, 3 years | 1; latest 1-for-10 on 2024-06-27 | Source 2024-06-27 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Francisco, California, United States | PCAOB Form AP 2026-03-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $306K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $80.9M | $13.2M | $34.6M | $46.6M | $14.5M | $288.2M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $78.7M | $17.3M | $30.7M | $60.8M | $78.5M | $276.8M | 10-Q 2026-08-04 |
| Q1 2026 2026-03-31 | $58.8M | $8.7M | $2.7M | $24.4M | $45.0M | $299.8M | 10-Q 2026-05-05 |
| Q4 2025 2025-12-31 | $69.8M | $268.1M | $22.0M | $40.6M | $52.5M | $294.3M | 10-K 2026-03-03 |
| Q3 2025 2025-09-30 | $69.5M | $27.9M | $24.0M | $48.5M | $60.0M | $282.1M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $101.7M | $59.6M | $30.5M | $53.4M | $60.0M | $267.9M | 10-Q 2026-08-04 |
| Q1 2025 2025-03-31 | $53.3M | $11.4M | -$893K | $45.7M | $60.0M | $203.1M | 10-Q 2026-05-05 |
| Q4 2024 2024-12-31 | $57.6M | $14.3M | $14.5M | $56.7M | $60.0M | $179.3M | 10-K 2026-03-03 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2024-08-02 |
| Latest annual report | 10-K | 2026-03-03 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-03 |
Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +12.1% |
| 1 month | -5.7% |
| 3 months | +9.0% |
| Year to date | +3.8% |
| 1 year | +11.5% |
| From 52-week high | -13.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SNDX | Syndax Pharmaceuticals Inc. | $9.13 | -3.39% | $821.6M |
| LTGO | Latigo Biotherapeutics Inc. | $12.60 | -3.89% | $835.4M |
| IRWD | Ironwood Pharmaceuticals Inc. | $4.85 | +0.41% | $802.9M |
| CTY | City Therapeutics Inc. | $16.98 | -6.19% | $854.6M |
| COLL | Collegium Pharmaceutical Inc. | $25.43 | +0.43% | $790.2M |
| IVA | Inventiva S.A. American Depository Shares | $3.32 | -9.78% | $784.5M |
| ORIC | Oric Pharmaceuticals Inc. | $7.52 | -4.33% | $779.5M |
| LXRX | Lexicon Pharmaceuticals Inc. | $1.75 | -2.23% | $779.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier